Christine Mills, MD
Interventional Cardiology · Aiken, SCNPI 1992142848
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (33.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Abbott at 45.2% of the total. Reporting peaked in 2020 at $10,528 and has fallen 71.9% since, to $2,958 in 2025.
Across 281 payments — averaging $96.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$12K
- Medtronic$6K
- Boston Scientific$4K
- Inari Medical, Inc.$1K
- Edwards Lifesciences$1K
- Shockwave Medical, Inc$473
- plus $2K from 25 others
What the payments were for
- Speaking & faculty fees$3,61313%
- Grants$9,00033%
- Travel & lodging$5,69421%
- Food & beverage$8,76132%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 32 | $12,252 |
| Medtronic(2 entities) | 37 | $5,687 |
| Boston Scientific | 58 | $4,255 |
| Inari Medical, Inc. | 65 | $1,211 |
| Edwards Lifesciences | 13 | $1,211 |
| Shockwave Medical, Inc | 8 | $473 |
| Medical Device Business Services, Inc. | 2 | $319 |
| Abiomed | 6 | $291 |
| Novartis | 16 | $287 |
| Stryker | 5 | $249 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $160 |
| Recor Medical Inc | 2 | $121 |
| Cardiva Medical, Inc. | 3 | $86 |
| E.r. Squibb & Sons, L.L.C. | 5 | $70 |
| Scpharmaceuticals Inc. | 2 | $40 |
| AstraZeneca | 3 | $39 |
| Merck | 2 | $37 |
| Pfizer | 2 | $35 |
| Johnson & Johnson | 2 | $31 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Teva Pharmaceuticals USA, Inc. | 1 | $26 |
| Amgen | 1 | $23 |
| Cardiovascular Systems Inc. | 1 | $22 |
| Chiesi USA, Inc. | 1 | $21 |
| W. L. Gore & Associates, Inc. | 1 | $19 |
| Angiodynamics, Inc. | 1 | $18 |
| Lantheus Medical Imaging, Inc. | 1 | $16 |
| Baxter Healthcare | 1 | $15 |
| Vital Connect, Inc | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Baylis Medical Company Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$4,173
- AMPLATZER AMULET$1,461
- VersaCross Access Solution$1,422
- Watchman$1,153
- FLOWTRIEVER CATHETER, S$890
- TRICLIP$693
- CT THROMBECTOMY SYSTEM KIT$585
- PASCAL$329
- Micra$326
- Carto 3$319
- WATCHMAN FLX$250
- Xience V coronary stent system$240
- CoreValve Evolut$154
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$151
- WATCHMAN Access System$149
- AMPLATZER Occluders$146
- FlowTriever$134
- MitraClip$120
- Paradise Ultrasound Renal Denervation System$102
How this compares
$27,080 in reported general payments places this provider in the 80th percentile of 117 interventional cardiology providers in South Carolina.
See all interventional cardiology providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 101 | $90,402 |
| Repatha SureclickEvolocumab | 16 | $15,478 |
| JardianceEmpagliflozin | 18 | $13,347 |
| XareltoRivaroxaban | 11 | $7,264 |
| Metoprolol Succinate | 98 | $1,433 |
| Candesartan Cilexetil | 12 | $1,027 |
| Atorvastatin Calcium | 98 | $836 |
| Ezetimibe | 22 | $795 |
| Losartan Potassium | 53 | $594 |
| Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid | 13 | $422 |
| Carvedilol | 47 | $313 |
| Nitroglycerin | 19 | $289 |
| Chlorthalidone | 17 | $285 |
| Rosuvastatin Calcium | 23 | $248 |
| Valsartan | 30 | $241 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $35 | $90,402101 claims |
| Johnson & JohnsonXarelto | $31 | $7,26411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 117 interventional cardiology providers in South Carolina.
Other interventional cardiology in Aiken
- Ansermo ArthurAiken$39K
- Daniel SteinbergCharleston$611K
- Brian BrownSpartanburg$389K
- Nicholas AmorosoPawleys Island$283K
- Robert LeonardiWest Columbia$203K
- Anbukarasi MaranCharleston$132K
- Jesse JorgensenGreenville$102K
- Thomas TodoranPawleys Island$95K
- Michael CryerColumbia$92K
- Josh DollGreenville$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.